IDT Australia Ltd (ASX: IDT) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

IDT Australia Limited Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $137.92 million
P/E Ratio 62.11
Dividend Yield N/A
Shares Outstanding 239.86 million
Earnings per share 0.009
Dividend per share N/A
Year To Date Return 202.70%
Earnings Yield 1.61%
Franking N/A
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Should you invest $1,000 in right now?

Before you consider , you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

IDT Australia Ltd (ASX: IDT)
Latest News

IDT ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About IDT Australia Ltd

IDT Australia Ltd produces, develops, and supplies pharmaceutical products. It is engaged in the provision of research and development and other technical services for the pharmaceutical and allied industries. The company is involved in the manufacture of Active Pharmaceutical Ingredients (API) and Finished Dose Forms (FDF), microbiological and analytical testing, clinical packaging, and pharmacy services.

IDT Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
26 Oct 2021 $0.58 $-0.02 -3.39% 476,617 $0.59 $0.60 $0.56
25 Oct 2021 $0.59 $0.03 5.36% 708,406 $0.58 $0.59 $0.56
22 Oct 2021 $0.56 $0.03 5.61% 439,871 $0.53 $0.57 $0.53
21 Oct 2021 $0.54 $-0.03 -5.31% 976,151 $0.56 $0.56 $0.52
20 Oct 2021 $0.57 $-0.03 -5.04% 551,864 $0.59 $0.59 $0.57
19 Oct 2021 $0.60 $0.02 3.45% 237,409 $0.59 $0.60 $0.59
18 Oct 2021 $0.58 $-0.04 -6.50% 1,252,563 $0.62 $0.63 $0.58
15 Oct 2021 $0.62 $-0.05 -7.58% 1,889,854 $0.66 $0.69 $0.62
14 Oct 2021 $0.66 $0.06 10.00% 2,166,185 $0.62 $0.67 $0.62
13 Oct 2021 $0.60 $0.01 1.68% 1,203,187 $0.63 $0.65 $0.59
12 Oct 2021 $0.60 $-0.03 -4.80% 477,541 $0.62 $0.63 $0.60
11 Oct 2021 $0.63 $-0.01 -1.59% 207,546 $0.63 $0.64 $0.61
08 Oct 2021 $0.63 $-0.02 -3.10% 188,589 $0.65 $0.65 $0.62
07 Oct 2021 $0.65 $0.05 8.33% 502,637 $0.61 $0.65 $0.59
06 Oct 2021 $0.60 $0.00 0.00% 590,812 $0.60 $0.62 $0.58
05 Oct 2021 $0.60 $-0.03 -4.80% 240,393 $0.61 $0.62 $0.59
04 Oct 2021 $0.63 $-0.02 -3.13% 195,342 $0.64 $0.64 $0.61
01 Oct 2021 $0.64 $-0.01 -1.54% 392,288 $0.64 $0.65 $0.63
30 Sep 2021 $0.65 $-0.02 -2.99% 578,397 $0.67 $0.67 $0.65
29 Sep 2021 $0.67 $-0.01 -1.47% 1,540,547 $0.69 $0.69 $0.65
28 Sep 2021 $0.68 $0.05 7.87% 664,523 $0.64 $0.68 $0.64

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Alan David Fisher Non-Executive DirectorNon-Executive Chairman Jun 2015
Mr Fisher is experienced corporate advisor and public company director. His main areas of experience include mergers and acquisitions, public and private equity raisings, business restructurings and strategic advice. Currently, he is Non-Executive Chair of Centrepoint Alliance Ltd, Non-Executive Director and Chair of Audit and Risk Committees of Bionomics Ltd and Thorney Technologies Ltd, and Non Executive Director of Simavita Ltd. He is a member of the Risk committee.
Mr Michael John Kotsanis Non-Executive Director Mar 2020
Mr Kotsanis over 30 years of strategic and operational experience in the global pharmaceutical industry. Michael was appointed as CEO of Acrux Ltd in November 2014. He was formerly the Chief Commercial Officer and a Board Member of Synthon Holding BV, a Dutch based international pharmaceutical company with revenue over EUR250 million, a position he held for four years. Prior to Synthon, he served as President, Europe, Middle East and Africa, for Hospira. Michael joined Hospira following its acquisition of Mayne Pharma in 2007, where he had served as President, Asia Pacific from 2002. He joined Mayne following their acquisition of FH Faulding in 2001, where he held responsibility for commercial activities of the pharmaceutical business in Australia and New Zealand. Michael was formerly a Board Member of the European Generics Association and a Director of the Generic Medicines Industry of Australia. He is a member of the Risk committee.
Mr Hugh Nigel Burrill Non-Executive Director Oct 2015
Mr Burrill was Corporate Vice President, Global Pharma Research & Development, Hospira Inc where he was responsible for overall pipeline portfolio management, and research and development of generic and specialty pharmaceuticals. Prior to this he held senior international roles within Hospira Inc and the original Mayne Pharma Ltd and currently provides consulting services in pharmaceutical strategic management, product development, regulatory affairs and intellectual property. He is Chair of the Risk committee.
Ms Maria (Mary) Elisabeth Sontrop Non-Executive Director Mar 2017
Ms Sontrop has international experience in the biopharmaceutical sector across manufacturing operations, quality, and business integration. During 28 years with CSL Limited (ASX: CSL), Mary was an integral part of CSL's globalisation through a series of major acquisitions. This included primary responsibility for the turnaround of unprofitable manufacturing operations. Subsequently as head of global plasma manufacturing, she delivered a globally integrated manufacturing network spanning four countries. As head of CSL's Australia and New Zealand pharmaceutical business.
Dr David Sparling Joint Company SecretaryChief Executive Officer Feb 2018
-
Ms Ancila Desai Chief Financial OfficerJoint Company Secretary Jun 2020
-
Ancila Desai Chief Financial OfficerJoint Company Secretary
-
Paul McDonald Head of Quality and Development
-
David Sparling Joint Company SecretaryChief Executive Officer
-
Jim Sosic Vice President Operations Supply and Infrastructure
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
UBS Nominees Pty Ltd 20,402,924 8.51%
HSBC Custody Nominees (Australia) Limited 19,773,269 8.24%
One Managed Invt Funds Ltd 18,161,934 7.57%
Citicorp Nominees Pty Limited 15,811,239 6.59%
One Fund Services Ltd 8,398,434 3.50%
Brispot Nominees Pty Ltd 8,004,797 3.34%
Mr Anthony John Huntley 7,500,000 3.13%
Graeme Leslie Blackman 7,029,710 2.93%
CS Third Nominees Pty Limited 6,141,162 2.56%
CS Fourth Nominees Pty Limited 5,838,039 2.43%
Jamplat Pty Ltd 5,725,000 2.39%
J P Morgan Nominees Australia Pty Limited 4,786,001 2.00%
I'Rom Group Co Ltd 3,766,035 1.57%
Mr Rodney Bruce Ebsworth 3,750,000 1.56%
Picherit'S Farm Pty Ltd 3,500,000 1.46%
Paulene Blackman 3,457,737 1.44%
David Sparling 2,936,621 1.18%
Goen Investments Pty Ltd 2,500,000 1.04%
Mr Anthony John Huntley (i) 2,500,000 1.04%
Mr Gavin George Rogers & Ms Kathryn Ann Rogers 2,500,000 1.04%

Profile

since

Note